Form 4: Stoke Therapeutics CEO Exercises Stock Options and Receives Restricted Stock Units

Stoke Therapeutics CEO, Edward M. Kaye, exercised stock options and received restricted stock units, resulting in a change in his beneficial ownership of the company's stock.

Summary

• Edward M. Kaye, CEO of Stoke Therapeutics, executed a transaction involving the company's stock on December 1, 2024.
• Mr. Kaye acquired 21,591 shares of common stock through the exercise of stock options.
• He also received 21,591 restricted stock units (RSUs) that will vest on December 1, 2024, and an additional 4,317 RSUs that will vest on December 1, 2025.
• The exercise price for the stock options was $0.
• Following these transactions, Mr. Kaye directly owns 48,591 shares of common stock and 4,317 RSUs that will vest in 2025.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which are generally viewed positively as they align management's interests with shareholders. There are no indications of negative sentiment.

Positives

• The vesting of restricted stock units aligns the CEO's interests with the long-term performance of the company.
• The exercise of stock options demonstrates the CEO's confidence in the company's future prospects.

Future Outlook

The restricted stock units are subject to continued service to the Issuer, indicating a commitment to the company's future.

Industry Context

This type of transaction is common for executive compensation in publicly traded companies, aligning management's interests with shareholders.

Comparison to Industry Standards

• Stock option exercises and RSU grants are standard practice for executive compensation in the biotechnology industry.
• Many comparable companies, such as BioMarin Pharmaceutical and Sarepta Therapeutics, use similar equity-based compensation plans to incentivize their executives.
• The vesting schedules for the RSUs are typical, with vesting occurring over a period of one to two years, which is consistent with industry norms.

Stakeholder Impact

• The transaction increases the CEO's stake in the company, potentially aligning his interests more closely with shareholders.
• The vesting of RSUs is contingent on continued service, which may encourage the CEO's long-term commitment to the company.

Key Dates

Keywords

Stoke Therapeutics, stock options, restricted stock units, beneficial ownership, insider trading, executive compensation, equity securities, CEO, Edward M. Kaye